

Scot Garg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6659534/publications.pdf>

Version: 2024-02-01

149
papers

10,310
citations

76196

40
h-index

33814

99
g-index

156
all docs

156
docs citations

156
times ranked

7751
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
2	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2010, 363, 136-146.	13.9	608
3	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> . 2018, 392, 940-949.	6.3	555
4	Assessment of the SYNTAX score in the Syntax study. <i>EuroIntervention</i> , 2009, 5, 50-56.	1.4	480
5	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S1-S42.	1.2	447
6	Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 38, S1-S52.	0.6	405
7	Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1357-1365.	1.2	363
8	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S43-S78.	1.2	278
9	A New Tool for the Risk Stratification of Patients With Complex Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 317-326.	1.4	236
10	5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1093-1101.	1.2	218
11	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	1.2	216
12	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 56, 272-277.	1.2	198
13	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of Sirolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. <i>European Heart Journal</i> , 2011, 32, 3115-3127.	1.0	136
14	Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 66-75.	1.1	132
15	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the 'All-Comers' LEADERS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 47-56.	1.4	109
16	New concepts in the design of drug-eluting coronary stents. <i>Nature Reviews Cardiology</i> , 2013, 10, 248-260.	6.1	107
17	Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. <i>American Heart Journal</i> , 2011, 161, 771-781.	1.2	106
18	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	1.2	101

#	ARTICLE	IF	CITATIONS
19	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 432-441.	1.1	98
20	A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1190-1198.	1.1	92
21	3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1190-1198.	1.1	89
22	Impact of Completeness of Revascularization on the Five-Year Outcome in Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Patients (from the ARTS-II Study). <i>American Journal of Cardiology</i> , 2010, 106, 1369-1375.	0.7	76
23	Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 52-60.	2.9	76
24	Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1622-1639.	1.2	73
25	In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. <i>EuroIntervention</i> , 2010, 5, 932-938.	1.4	73
26	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 T Patients Enrolled in Contemporary Coronary Stent Trials. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 645-653.	1.1	70
27	The SYNTAX score revisited: A reassessment of the SYNTAX score reproducibility. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 946-952.	0.7	69
28	Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 713-736.	1.2	66
29	First-in-Man Clinical Use of Combined Near-Infrared Spectroscopy and Intravascular Ultrasound. <i>Journal of the American College of Cardiology</i> , 2010, 56, 314.	1.2	59
30	5-Year Follow-Up of Coronary Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 317-323.	1.1	58
31	A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. <i>European Heart Journal</i> , 2011, 32, 294-304.	1.0	58
32	First use in patients of a combined near infra-red spectroscopy and intra-vascular ultrasound catheter to identify composition and structure of coronary plaque. <i>EuroIntervention</i> , 2010, 5, 755-756.	1.4	52
33	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010, 105, 475-479.	0.7	49
34	Long-Term Clinical Results Following Stenting of the Left Main Stem. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 584-594.	1.1	49
35	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
36	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. <i>EuroIntervention</i> , 2010, 6, 233-239.	1.4	49

#	ARTICLE	IF	CITATIONS
37	Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 467-478.	0.7	47
38	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the <scp>LEADERS</scp> all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E248-60.	0.7	44
39	Takotsubo Cardiomyopathy: A Review of the Literature. <i>Angiology</i> , 2010, 61, 166-173.	0.8	41
40	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. <i>EuroIntervention</i> , 2010, 6, 195-205.	1.4	41
41	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	1.4	39
42	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37
43	Left Radial versus Right Radial Approach for Coronary Artery Catheterization: A Prospective Comparison. <i>Journal of Interventional Cardiology</i> , 2012, 25, 203-209.	0.5	37
44	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
45	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 199-206.	0.7	32
46	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2761-2773.	1.2	32
47	Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice?. <i>European Heart Journal</i> , 2010, 31, 1032-1035.	1.0	30
48	Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 889-899.	1.2	30
49	External Validation of the SYNTAX Score II 2020. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1227-1238.	1.2	30
50	Clinical and Angiographic Risk Assessment in Patients With Left Main Stem Lesions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 891-901.	1.1	29
51	In Vivo 3D Distribution of Lipid-Core Plaque in Human Coronary Artery as Assessed by Fusion of Near Infrared Spectroscopy-Intravascular Ultrasound and Multislice Computed Tomography Scan. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, e6-7.	1.3	29
52	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. <i>European Heart Journal</i> , 2018, 39, 3381-3389.	1.0	29
53	Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: Insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 979-986.	0.7	28
54	Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 1012-1017.	0.7	28

#	ARTICLE	IF	CITATIONS
55	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
56	Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. <i>EuroIntervention</i> , 2009, 5, F109-F111.	1.4	27
57	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015, 187, 111-115.	0.8	26
58	Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. <i>Scientific Reports</i> , 2018, 8, 1229.	1.6	26
59	Serial Morphological Changes of Side-Branch Ostium after Paclitaxel-Coated Balloon Treatment of <i>De Novo</i> Coronary Lesions of Main Vessels. <i>Yonsei Medical Journal</i> , 2016, 57, 606.	0.9	25
60	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. <i>Journal of the American College of Cardiology</i> , 2022, 80, 63-88.	1.2	25
61	Benefits of and safety concerns associated with drug-eluting coronary stents. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 449-470.	0.6	24
62	Seizure-associated takotsubo cardiomyopathy presenting with unheralded ventricular fibrillation. <i>International Journal of Cardiology</i> , 2012, 162, e21-e23.	0.8	24
63	Comparison of Paclitaxel-Coated Balloon Treatment and Plain Old Balloon Angioplasty for <i>De Novo</i> Coronary Lesions. <i>Yonsei Medical Journal</i> , 2016, 57, 337.	0.9	23
64	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
65	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. <i>European Heart Journal</i> , 2021, 43, 56-67.	1.0	23
66	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization in Patients With Heavy Calcification. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 193-204.	1.1	23
67	Outcomes of Percutaneous Coronary Intervention Performed at Offsite Versus Onsite Surgical Centers in the United Kingdom. <i>Journal of the American College of Cardiology</i> , 2015, 66, 363-372.	1.2	22
68	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 859-866.	0.7	21
69	Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 695-703.	0.7	21
70	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial. <i>EuroIntervention</i> , 2011, 7, 605-613.	1.4	21
71	Effect of Sex Difference of Coronary Microvascular Dysfunction on Long-Term Outcomes in Deferred Lesions. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1669-1679.	1.1	20
72	Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 51-58.	0.7	19

#	ARTICLE	IF	CITATIONS
73	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
74	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , 2011, 6, 928-935.	1.4	19
75	IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 914-918.	0.7	18
76	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	0.8	18
77	Bifurcation lesions: Functional assessment by fractional flow reserve vs. anatomical assessment using conventional and dedicated bifurcation quantitative coronary angiogram. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 817-823.	0.7	17
78	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
79	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. <i>European Heart Journal</i> , 2022, 43, 1334-1344.	1.0	17
80	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. <i>American Heart Journal</i> , 2011, 162, 1069-1079.e2.	1.2	16
81	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
82	Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 384-407.	1.2	16
83	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
84	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	1.4	16
85	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2022, 18, e377-e388.	1.4	16
86	Predicted and Observed Mortality at 10 Years in Patients With Bifurcation Lesions in the SYNTAX Trial. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1231-1242.	1.1	16
87	Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities. <i>Cardiovascular Ultrasound</i> , 2011, 9, 2.	0.5	15
88	Revascularization treatment of stable coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 195-212.	0.9	15
89	Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 1057-1064.	2.0	15
90	Paclitaxel-coated balloon treatment for functionally nonsignificant residual coronary lesions after balloon angioplasty. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1339-1347.	0.7	15

#	ARTICLE	IF	CITATIONS
91	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	1.4	15
92	Clinical Indications for Intravascular Ultrasound Imaging. <i>Echocardiography</i> , 2010, 27, 1282-1290.	0.3	14
93	Remote ischemic preconditioning in hemodialysis: a pilot study. <i>Heart and Vessels</i> , 2014, 29, 58-64.	0.5	14
94	Prospective randomized trial of paclitaxel-coated balloon versus bare-metal stent in high bleeding risk patients with de novo coronary artery lesions. <i>Coronary Artery Disease</i> , 2019, 30, 425-431.	0.3	14
95	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
96	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1087-1095.	1.8	14
97	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
98	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
99	Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China. <i>JAMA Network Open</i> , 2022, 5, e2214594.	2.8	14
100	Gender differences in plaque characteristics of culprit lesions in patients with ST elevation myocardial infarction. <i>Heart and Vessels</i> , 2016, 31, 1767-1775.	0.5	12
101	Plaque modification and stabilization after paclitaxel-coated balloon treatment for de novo coronary lesions. <i>Heart and Vessels</i> , 2019, 34, 1113-1121.	0.5	12
102	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006581.	0.9	10
103	Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study. <i>EuroIntervention</i> , 2011, 6, 1060-1067.	1.4	10
104	Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 821380.	1.1	9
105	Impact of Dissection after Drug-Coated Balloon Treatment of De Novo Coronary Lesions: Angiographic and Clinical Outcomes. <i>Yonsei Medical Journal</i> , 2020, 61, 1004.	0.9	8
106	Sex-specific difference of in-hospital mortality from COVID-19 in South Korea. <i>PLoS ONE</i> , 2022, 17, e0262861.	1.1	8
107	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. <i>EuroIntervention</i> , 2022, 18, 492-502.	1.4	8
108	Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry. <i>BMJ Open</i> , 2019, 9, e026578.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Have We Overdefined Periprocedural Myocardial Infarction to the Point of Extinction?. JACC: Cardiovascular Interventions, 2021, 14, 1635-1638.	1.1	7
110	Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart, 2022, 108, 1784-1791.	1.2	7
111	Association of Inter-Arm Systolic Blood Pressure Difference with Coronary Atherosclerotic Disease Burden Using Calcium Scoring. Yonsei Medical Journal, 2017, 58, 954.	0.9	6
112	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	0.7	6
113	Predicting 2-year all-cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	0.7	6
114	Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. Cardiology Journal, 2021, 28, 615-622.	0.5	6
115	Coronary angioplasty: do we need to EuroSCORE?. Nature Reviews Cardiology, 2009, 6, 267-268.	6.1	5
116	Reproducibility of coronary artery calcium measurements using 0.8-mm-thickness 256-slice coronary CT. Japanese Journal of Radiology, 2014, 32, 677-684.	1.0	5
117	A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions. Yonsei Medical Journal, 2017, 58, 99.	0.9	5
118	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	0.7	5
119	A Clinical Risk Score to Predict In-hospital Mortality from COVID-19 in South Korea. Journal of Korean Medical Science, 2021, 36, e108.	1.1	5
120	Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?. European Heart Journal, 2021, 42, 2665-2669.	1.0	5
121	The contribution of gender and age on early and late mortality following ST-segment elevation myocardial infarction: results from the Korean Acute Myocardial Infarction National Registry with Registries. Journal of Geriatric Cardiology, 2018, 15, 205-214.	0.2	5
122	Quantitative Angiographic Assessment of Aortic Regurgitation Following 11 TAVR Devices: An Update of a Multicenter Pooled Analysis. , 2022, , 100037.		5
123	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	1.4	5
124	An Update on Drug-Eluting Stents. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 61-78.	0.4	4
125	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology, 2020, 320, 27-34.	0.8	4
126	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	0.8	4
128	Drug-coated balloon treatment for nonsmall de-novo coronary artery disease: angiographic and clinical outcomes. Coronary Artery Disease, 2021, 32, 534-540.	0.3	4
129	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	1.5	4
130	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. American Heart Journal, 2021, 239, 19-26.	1.2	4
131	Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008055.	0.9	4
132	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	1.6	4
133	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	0.7	4
134	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	1.5	3
135	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	3
136	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 547-556.	1.4	3
137	Impact of paclitaxel-coated balloon versus newer-generation drug-eluting stent on periprocedural myocardial infarction in stable angina patients. Coronary Artery Disease, 2018, 29, 403-408.	0.3	2
138	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	0.8	2
139	Sex-Related Outcomes of Successful Drug-Coated Balloon Treatment in De Novo Coronary Artery Disease. Yonsei Medical Journal, 2021, 62, 981.	0.9	2
140	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	1.2	1
141	Letter by Garg et al Regarding Article, "Percutaneous Coronary Intervention at Centers With and Without On-Site Surgical Backup: An Updated Meta-Analysis of 23 Studies", Circulation, 2016, 133, e406.	1.6	0
142	34...Next generation P2Y12 inhibitors improve survival in ACS: an analysis from the british cardiovascular intervention society database. , 2021, , .		0
143	Ten-year all-cause mortality following staged percutaneous revascularization in patients with complex coronary artery disease. Cardiovascular Revascularization Medicine, 2021, , .	0.3	0
144	A Case of Aneurysm Occurring at the Dissection Site after Intervention with Drug-Coated Balloon. Korean Circulation Journal, 2021, 51, 376.	0.7	0

#	ARTICLE	IF	CITATIONS
145	How should I treat a complex Post-CABG patient?. EuroIntervention, 2009, 5, 627-632.	1.4	0
146	Research Utility of Intravascular Ultrasound. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 109-136.	0.2	0
147	Analysis of the Existing Data Fusion Methodologies for 3D Coronary Imaging. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 278-291.	0.2	0
148	Letter by Kawashima et al Regarding Article, "Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease". Circulation: Cardiovascular Interventions, 2022, 15, e012080.	1.4	0
149	Are We Unisex When Undergoing Left Main Revascularization?. , 2022, , 100345.		0